Welcome to our dedicated page for Quantum-Si Incorporated SEC filings (Ticker: QSIAW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Quantum-Si Incorporated's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Quantum-Si Incorporated's regulatory disclosures and financial reporting.
Quantum-Si Inc Chief Product Officer John S. Vieceli received new equity awards. On March 12, 2026, he was granted options to buy 468,508 shares of Class A common stock at an exercise price of $0.976 per share, vesting in equal quarterly installments beginning on June 20, 2026 until fully vested, subject to continued service.
He also received 391,681 restricted stock units, each representing one share of common stock upon vesting, on the same vesting schedule starting June 20, 2026. Following these awards, Vieceli directly holds 1,192,654 shares of Class A common stock. These are compensation-related grants rather than open-market purchases or sales.
Quantum-Si Inc President & CEO Jeffrey Alan Hawkins reported equity compensation awards rather than open-market trades. He received a stock option covering 1,561,695 shares of Class A common stock at an exercise price of $0.976 per share, expiring on March 12, 2036. The option vests in equal quarterly installments beginning on June 20, 2026, subject to continued service. He also received 1,305,606 restricted stock units, each representing one share of common stock, which vest in four equal annual installments starting on April 20, 2027, subject to continued service. Following the RSU grant, his direct holdings of Class A common stock increased to 3,883,624 shares.
Quantum-Si Inc reported that its General Counsel and Corporate Secretary, Christian LaPointe, received new equity awards. He was granted 261,121 shares of Class A common stock in the form of restricted stock units and a stock option for 312,339 shares at an exercise price of $0.976 per share. Both the RSUs and the option vest in equal quarterly installments beginning on June 20, 2026, subject to continued service. Following these awards, LaPointe directly owns 1,209,976 shares of Class A common stock.
Quantum-Si Inc director Charles R. Kummeth reported an open-market purchase of 500,000 shares of Class A common stock on March 5, 2026. The weighted average purchase price was $0.9196 per share, with individual trades executed between $0.8906 and $0.9735 per share. Following this transaction, he directly holds 855,000 shares of Quantum-Si common stock.
Quantum-Si Inc director Paula Dowdy purchased Class A common stock in an open-market transaction. On March 5, 2026, she bought 109,890 shares at a weighted average price of $0.9505 per share, and held 269,107 shares directly after the trade.
The footnote explains that the $0.9505 figure is a weighted average, with actual purchase prices ranging from $0.9051 to $0.9730 per share. Detailed price breakdowns are available upon request from regulators, the company, or its security holders.
Quantum-Si Incorporated reported wider full-year losses while preparing for its next-generation Proteus platform launch. For 2025, revenue was $2.4 million, with gross profit of $1.2 million and a gross margin of 47%. The company posted a 2025 net loss of $101.3 million, similar to the prior year, but reduced adjusted operating expenses to $86.3 million from $99.0 million.
In the fourth quarter of 2025, revenue was $0.5 million with a 27% gross margin and a net loss of $17.6 million. Management highlighted significant cost discipline and one-time litigation charges of $18.7 million during 2025. As of December 31, 2025, cash, cash equivalents and marketable securities totaled $215.8 million, which the company believes funds operations into the second quarter of 2028.
For 2026, Quantum-Si issued guidance for revenue of approximately $1.0 million, adjusted total operating expenses of $98.0 million or less, and total cash usage of $93.0 million or less. The company expects 2026 to be a transition year, intentionally moderating revenue as it embeds upgrade credits and placement programs to support a stronger commercial launch of the Proteus system, which has a list price of $425,000 and is targeted for launch by the end of 2026.
Quantum-Si Inc director Amir Jafri received a grant of 114,055 stock options on Class A Common Stock at an exercise price of $0.00 per share. The options vest in equal monthly installments beginning on March 31, 2026, subject to continued service. Following this, he directly holds 115,942 Class A shares.
Jonathan M. Rothberg and affiliated entities disclosed holdings in Quantum-Si Inc. across both Class A and Class B stock classes and filed Amendment No. 4 to their Schedule 13D. For Class A, the filing reports beneficial ownership of 14,276,415 shares, representing 7.8% of the 182,557,698 Class A shares outstanding as of July 31, 2025; that amount includes personal shares, options exercisable within 60 days, and shares held by trusts and affiliated entities.
The filing also reports beneficial ownership of 19,937,500 Class B shares, representing 100% of outstanding Class B stock. As part of estate planning, trusts for Dr. Rothberg's children adopted a Rule 10b5-1 trading plan allowing sales of up to 8,973,841 Class A shares during the plan period from January 14, 2026 through January 14, 2027, subject to minimum price parameters; no assurance any sales will occur. The amendment adds the Rule 10b5-1 plan as Exhibit 5.